X
[{"orgOrder":0,"company":"Torrent Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Torrent Pharma launches First and Only Generic Version of Keveyis\u00ae (dichlorphenamide) Tablets in the United States","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Torrent Pharmaceuticals Limited","sponsor":"Cycle Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New US Product, ORMALVI\u2122 (dichlorphenamide) Tablets, Launches for Primary Periodic Paralysis (PPP) Treatment","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"May 2024","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"},{"orgOrder":0,"company":"Torrent Pharmaceuticals Limited","sponsor":"Cycle Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Tiopronin Delayed-Release Tablets Launch For Cystinuria Treatment","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"May 2024","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved"}]
Find Clinical Drug Pipeline Developments & Deals by Torrent Pharmaceuticals Limited
Filters
Companies By Therapeutic Area
Details:
Tiopronin is an active reducing agent which undergoes thiol-disulfide exchange with cystine to form a mixed disulfide of tiopronin-cysteine. It is indicated for cystinuria.
Lead Product(s):
Tiopronin
Therapeutic Area: Nephrology
Product Name: Tiopronin-Generic
Highest Development Status: Approved
Product Type: Small molecule
Recipient:
Cycle Pharmaceuticals
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 13, 2024
Details:
Ormalvi (dichlorphenamide) is a carbonic anhydrase inhibitor. The generic version has been approved and is indicated for the treatment of primary hyperkalemic periodic paralysis and related variants.
Lead Product(s):
Dichlorphenamide
Therapeutic Area: Genetic Disease
Product Name: Ormalvi
Highest Development Status: Approved
Product Type: Small molecule
Recipient:
Cycle Pharmaceuticals
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 08, 2024
Details:
Dichlorphenamide is a carbonic anhydrase inhibitor. The generic version has been approved and is indicated for the treatment of primary hyperkalemic periodic paralysis and related variants.
Lead Product(s):
Dichlorphenamide
Therapeutic Area: Neurology
Product Name: Keveyis-Generic
Highest Development Status: Approved
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
April 06, 2023